Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

AIMS: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalization for heart failure (HHF) and composite kidney outcomes, but the mediators underlying these benefits are unknown. MATERIALS AND METHODS: Among participants from VERTIS CV, a trial of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Segar, Matthew W., Kolkailah, Ahmed A., Frederich, Robert, Pong, Annpey, Cannon, Christopher P., Cosentino, Francesco, Dagogo‐Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Liu, Chih‐Chin, Maldonado, Mario, Liu, Jie, Cater, Nilo B., Pandey, Ambarish, Cherney, David Z. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357198/
https://www.ncbi.nlm.nih.gov/pubmed/35603908
http://dx.doi.org/10.1111/dom.14769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357198/
https://www.ncbi.nlm.nih.gov/pubmed/35603908
http://dx.doi.org/10.1111/dom.14769

Ejemplares similares